All In Biotech

Drug Trial Radar · NCT01871805

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib

Last checked: Nov 19, 2026Latest source record: Aug 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

134

Actual

Start

Sep 30, 2013

Primary completion

Oct 24, 2014

Study completion Aug 31, 2017

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of alectinib in participants with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment. In Phase I, cohorts of participants will receive escalating doses of alectinib orally twice daily. In Phase II, patients who failed crizotinib treatment will receive the recommended phase II dose.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • AlectinibDrug

    Participants will receive alectinib as described in the arm descriptions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs): Phase ITime frame: Throughout Cycle 1 of Phase I (21 days)
  2. Recommended Phase II Dose (RP2D): Phase ITime frame: Throughout Cycle 1 of Phase I (21 days)
  3. Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Independent Review Committee (IRC): Phase IITime frame: Cycle 1 Day 1 up to 194 weeks (assessed at every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter) (1 cycle = 21 days)

Locations

42 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California Irvine

    Irvine, California

  • UCSD Moores Cancer Center

    La Jolla, California

  • Loma Linda Cancer Center

    Loma Linda, California

  • UCLA

    Los Angeles, California

  • Univ of Colorado Canc Ctr

    Aurora, Colorado

  • National Jewish Health

    Denver, Colorado

  • Lynn Regional Cancer Center West

    Boca Raton, Florida

  • Florida Hospital Cancer Inst

    Orlando, Florida

  • UF Health Orlando

    Orlando, Florida

  • H. Lee Moffitt Cancer Center and Research Inst.

    Tampa, Florida

  • University of Illinois Cancer Center

    Chicago, Illinois

  • Monroe Medical Associates; Ingalls Memorial Hosp

    Harvey, Illinois

  • Massachussets General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Can Ins

    Boston, Massachusetts

  • Newton-Wellesley Hospital

    Newton, Massachusetts

  • St. Joseph Mercy Hospital; Cancer Care Center.

    Ann Arbor, Michigan

  • Wayne State Uni ; Karmanos Cancer Center

    Detroit, Michigan

  • Hackensack Univ Med Ctr

    Hackensack, New Jersey

  • Roswell Park Cancer Inst.

    Buffalo, New York

  • Memorial Sloan-Kettering Cancer Center

    Commack, New York

  • Richmond University Medical Center; Pharmacy Department

    Staten Island, New York

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Gabrail Cancer Center

    Canton, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Providence Portland Med Ctr

    Portland, Oregon

  • Oregon Health & Science Uni

    Portland, Oregon

  • St. Luke's Hospital; Pharmacy Department

    Bethlehem, Pennsylvania

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Cancer Pavillion

    Pittsburgh, Pennsylvania

  • MUSC Hollings Cancer Center

    Charleston, South Carolina

  • Center for Biomedical Research LLC

    Knoxville, Tennessee

  • Texas Oncology-Baylor Sammons Cancer Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Swedish Cancer Inst.

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.